Notably, the pharmacological inhibitors of A-FABP such as BMS309403 (ref. 67) and the recent identified A-FABP monoclonal antibody CA33 (ref. 68) alleviate metabolic and cardiovascular disorders in animals. This evidence concerns the gene FABP4 and cardiovascular disorder.